PHARMExcel was delighted to have sponsored the UKCRF Network’s Annual Conference in Nottingham and to support this year’s conference theme ‘Leading life changing research’.
The UK clinical research landscape is multi-faceted and has key strengths in many areas including the NHS, NIHR, UK CRF Network, and leading academic centres. Despite that, there has been a notable steady decline in commercial clinical trials initiated since 2012 in all phases.
How to create a more attractive research environment
To move forward successfully there needs to be a collaborative effort to create a more attractive environment that can support research as well as maintain many of the developments that were a by-product of the pandemic – including expedited reviews and rapid approvals. Additionally, focusing on implementing equity and diversity in trial designs should become a priority.
By involving UK CRFs as well as CROs, clinical trials can benefit from the added NHS, academic and industry expertise that is required to develop the new medicines and technology needed to support the health and wealth of the nation.
Accelerating clinical trial delivery through Trial Acceleration Networks
One way to accelerate new and innovative ways to deliver trials is through the adoption of Clinical Trial Acceleration Networks (CTANs). The UK Government has committed £20 million over two years to establish two to three CTANs, most likely in the research areas of infectious disease vaccines, cancer and dementia.
This funding will be used to deliver innovative, efficient and effective approaches for clinical trials, enabling the UK to lead globally on the delivery of high-quality research. These networks will support emerging place-based knowledge clusters to ensure that research delivery is spread both nationally and at a local level. The CTANs will be used as exemplars for the development and spread of new approaches for the benefit of the whole clinical research system.
